PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 71 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 2.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $331,000 | -61.9% | 87,041 | -48.9% | 0.00% | 0.0% |
| Q4 2019 | $868,000 | -54.3% | 170,480 | -58.3% | 0.00% | -50.0% |
| Q1 2019 | $1,899,000 | +17.1% | 409,199 | +6.0% | 0.01% | 0.0% |
| Q4 2018 | $1,622,000 | +1128.8% | 386,179 | +2103.6% | 0.01% | +500.0% |
| Q4 2014 | $132,000 | +7.3% | 17,525 | -24.2% | 0.00% | 0.0% |
| Q4 2013 | $123,000 | -15.2% | 23,109 | -29.2% | 0.00% | 0.0% |
| Q2 2013 | $145,000 | – | 32,629 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |